MeSH term
Frequency | Condition_Probility | Humans | 190 | 0.0 |
Cell Differentiation/physiology | 2 | 0.0 |
Cell Division/physiology | 2 | 0.0 |
Insulin-Like Growth Factor Binding Protein 3/metabolism | 2 | 13.0 |
Insulin-Like Growth Factor I/*physiology | 2 | 5.0 |
Insulin-Like Growth Factor II/physiology | 2 | 33.0 |
Receptor, IGF Type 1/metabolism | 3 | 9.0 |
Research Support, Non-U.S. Gov't | 96 | 0.0 |
Amino Acid Sequence | 9 | 0.0 |
Animals | 61 | 0.0 |
Carrier Proteins/*genetics | 2 | 0.0 |
Mice | 31 | 0.0 |
Models, Genetic | 2 | 0.0 |
Molecular Sequence Data | 22 | 0.0 |
Protein Structure, Tertiary | 5 | 0.0 |
Sequence Homology, Amino Acid | 2 | 0.0 |
Tumor Cells, Cultured | 20 | 0.0 |
Adult | 42 | 0.0 |
Female | 89 | 0.0 |
Cell Division | 9 | 0.0 |
DNA-Binding Proteins/*genetics | 2 | 0.0 |
Promoter Regions (Genetics) | 6 | 0.0 |
*Protein-Serine-Threonine Kinases | 5 | 0.0 |
Research Support, U.S. Gov't, P.H.S. | 41 | 0.0 |
Adolescent | 16 | 0.0 |
Age Factors | 5 | 0.0 |
Aged | 23 | 0.0 |
Child | 14 | 0.0 |
Comparative Study | 21 | 0.0 |
Drug Therapy, Combination | 2 | 0.0 |
English Abstract | 15 | 0.0 |
Male | 59 | 0.0 |
Middle Aged | 34 | 0.0 |
Pregnancy | 9 | 0.0 |
Time Factors | 14 | 0.0 |
Insulin-Like Growth Factor I/pharmacology | 8 | 4.0 |
Molecular Weight | 2 | 0.0 |
Precipitin Tests | 4 | 0.0 |
Recombinant Proteins/pharmacology | 2 | 0.0 |
Aging/*metabolism | 3 | 1.0 |
Cell Movement | 2 | 0.0 |
Cells, Cultured | 12 | 0.0 |
Insulin-Like Growth Factor I/*pharmacology | 9 | 6.0 |
Base Sequence | 19 | 0.0 |
Case-Control Studies | 5 | 0.0 |
Disease Models, Animal | 3 | 0.0 |
Linkage (Genetics) | 6 | 0.0 |
Oligonucleotide Array Sequence Analysis | 4 | 0.0 |
Rats | 10 | 0.0 |
Cattle | 4 | 0.0 |
Chromosomes, Human, Pair 12/*genetics | 2 | 1.0 |
Genetic Markers | 3 | 0.0 |
Swine/*genetics | 3 | 2.0 |
Catalysis | 2 | 0.0 |
Enzyme Activation | 3 | 0.0 |
Kinetics | 10 | 0.0 |
Phosphorylation | 6 | 0.0 |
Substrate Specificity | 2 | 0.0 |
Thermodynamics | 2 | 0.0 |
Rabbits | 4 | 0.0 |
Body Composition | 4 | 1.0 |
Child, Preschool | 7 | 0.0 |
Insulin-Like Growth Factor I/*genetics | 9 | 36.0 |
Human Growth Hormone/blood | 2 | 3.0 |
Insulin-Like Growth Factor Binding Protein 3/blood | 3 | 5.0 |
Insulin-Like Growth Factor I/analysis | 10 | 7.0 |
Linear Models | 2 | 0.0 |
Mutation | 5 | 0.0 |
Phenotype | 7 | 0.0 |
Signal Transduction | 11 | 0.0 |
Delayed-Action Preparations | 3 | 2.0 |
Insulin-Like Growth Factor I/*metabolism | 13 | 9.0 |
Treatment Outcome | 5 | 0.0 |
Insulin-Like Growth Factor I/genetics/*physiology | 3 | 75.0 |
Mice, Knockout | 3 | 0.0 |
RNA, Messenger/analysis | 6 | 0.0 |
Receptor, IGF Type 1/genetics/*physiology | 2 | 25.0 |
*Mutation | 2 | 0.0 |
In Vitro | 5 | 0.0 |
Blotting, Northern | 3 | 0.0 |
Down-Regulation | 3 | 0.0 |
Gene Expression | 6 | 0.0 |
Insulin-Like Growth Factor I/*pharmacology/physiology | 2 | 33.0 |
Biological Markers | 4 | 0.0 |
Cell Differentiation | 3 | 0.0 |
Species Specificity | 5 | 0.0 |
Alleles | 6 | 0.0 |
Genotype | 8 | 0.0 |
Insulin-Like Growth Factor I/*genetics/*metabolism | 2 | 50.0 |
Polymorphism, Genetic | 4 | 0.0 |
Risk Factors | 7 | 0.0 |
Sequence Analysis, DNA | 2 | 0.0 |
Transcription Factors/genetics | 3 | 0.0 |
Acromegaly/blood/*drug therapy | 3 | 21.0 |
Glucose Tolerance Test | 4 | 0.0 |
Insulin/blood | 5 | 0.0 |
Insulin-Like Growth Factor I/metabolism | 13 | 6.0 |
Octreotide/adverse effects/*therapeutic use | 2 | 40.0 |
Body Height | 3 | 1.0 |
Body Weight | 2 | 0.0 |
1-Phosphatidylinositol 3-Kinase/*metabolism | 2 | 0.0 |
Proto-Oncogene Proteins/*metabolism | 2 | 0.0 |
Sequence Alignment | 3 | 0.0 |
Somatomedins/*metabolism | 3 | 12.0 |
Phosphoproteins/*genetics | 2 | 0.0 |
Polymerase Chain Reaction | 11 | 0.0 |
Polymorphism, Genetic/*genetics | 2 | 0.0 |
Disease Progression | 2 | 0.0 |
Neoplasm Invasiveness | 2 | 0.0 |
Liver Neoplasms/*genetics | 2 | 1.0 |
Somatomedins/*genetics | 3 | 20.0 |
Chromosomes, Human, Pair 12 | 3 | 1.0 |
Body Mass Index | 3 | 0.0 |
Diet | 2 | 0.0 |
Insulin Resistance/*physiology | 2 | 2.0 |
Insulin-Like Growth Factor II/metabolism | 2 | 7.0 |
Aging/physiology | 2 | 1.0 |
*Gene Expression Regulation | 3 | 0.0 |
Gene Library | 2 | 0.0 |
Mice, Transgenic | 3 | 0.0 |
Restriction Mapping | 3 | 0.0 |
Sequence Homology, Nucleic Acid | 3 | 0.0 |
Injections, Subcutaneous | 2 | 0.0 |
Epidermal Growth Factor/pharmacology | 2 | 0.0 |
Aged, 80 and over | 4 | 0.0 |
Immunohistochemistry | 5 | 0.0 |
Cell Division/drug effects | 6 | 0.0 |
Cell Line | 10 | 0.0 |
Dose-Response Relationship, Drug | 6 | 0.0 |
Enzyme Inhibitors/*pharmacology | 2 | 0.0 |
Flow Cytometry | 2 | 0.0 |
Cells, Cultured/drug effects | 2 | 2.0 |
Muscle, Skeletal/*physiology | 2 | 2.0 |
*Apoptosis | 3 | 0.0 |
Growth Substances/*metabolism | 3 | 2.0 |
Prognosis | 2 | 0.0 |
Somatomedins/*analysis | 2 | 18.0 |
Genetic Predisposition to Disease | 2 | 0.0 |
Insulin-Like Growth Factor I/genetics | 4 | 19.0 |
Proteins/genetics | 2 | 0.0 |
Culture Media | 5 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 5 | 0.0 |
Insulin-Like Growth Factor I/physiology | 2 | 6.0 |
Cytosol/metabolism | 2 | 0.0 |
Enzyme Inhibitors/pharmacology | 2 | 0.0 |
Tetradecanoylphorbol Acetate/pharmacology | 3 | 0.0 |
Magnetic Resonance Imaging | 2 | 0.0 |
RNA, Messenger/genetics | 3 | 0.0 |
Insulin-Like Growth Factor I/*analysis | 5 | 9.0 |
Embryonic and Fetal Development | 2 | 0.0 |
Glucose/pharmacology | 3 | 2.0 |
Chick Embryo | 2 | 0.0 |
Cloning, Molecular | 3 | 0.0 |
Retrospective Studies | 2 | 0.0 |
Chromosome Mapping | 4 | 0.0 |
*Promoter Regions (Genetics) | 2 | 0.0 |
Syndrome | 3 | 0.0 |
Insulin-Like Growth Factor I/biosynthesis | 2 | 18.0 |
DNA/genetics | 3 | 0.0 |
C-Peptide/blood | 2 | 1.0 |
Cross-Sectional Studies | 2 | 0.0 |
Triglycerides/blood | 4 | 0.0 |
Antibodies/pharmacology | 2 | 0.0 |
Insulin/pharmacology | 3 | 1.0 |
DNA Primers | 4 | 0.0 |
Insulin-Like Growth Factor I/*biosynthesis/genetics | 2 | 33.0 |
Insulin-Like Growth Factor II/*biosynthesis/genetics | 2 | 14.0 |
Receptor, IGF Type 1/*biosynthesis/genetics | 2 | 50.0 |
Receptor, IGF Type 2/*biosynthesis/genetics | 2 | 100.0 |
Transcription, Genetic | 4 | 0.0 |
Energy Intake | 3 | 1.0 |
Insulin-Like Growth Factor Binding Protein 3/blood/drug effects | 2 | 66.0 |
Insulin-Like Growth Factor I/drug effects/metabolism | 2 | 40.0 |
Transfection | 5 | 0.0 |
3T3 Cells | 3 | 0.0 |
Culture Media, Serum-Free | 3 | 0.0 |
Protein Binding/drug effects | 2 | 0.0 |
Insulin/*pharmacology | 5 | 2.0 |
Electrophoresis, Polyacrylamide Gel | 3 | 0.0 |
Jurkat Cells | 2 | 0.0 |
Mice, Inbred BALB C | 2 | 0.0 |
Insulin/metabolism | 3 | 2.0 |
Models, Biological | 3 | 0.0 |
Receptor, IGF Type 1/*metabolism | 3 | 8.0 |
Receptor, Insulin/metabolism | 2 | 2.0 |
*Signal Transduction | 2 | 0.0 |
In Situ Hybridization | 2 | 0.0 |
Area Under Curve | 2 | 0.0 |
Combined Modality Therapy | 2 | 0.0 |
Body Height/physiology | 2 | 12.0 |
Body Weight/physiology | 2 | 2.0 |
Insulin-Like Growth Factor Binding Protein 3/*blood | 2 | 7.0 |
Analysis of Variance | 2 | 0.0 |
Evaluation Studies | 2 | 0.0 |
Infant | 3 | 0.0 |
Growth Hormone/blood | 8 | 3.0 |
Radioimmunoassay | 3 | 0.0 |
Culture Media, Conditioned/pharmacology | 2 | 1.0 |
Gene Expression Regulation/genetics | 2 | 1.0 |
Cell Line, Tumor | 2 | 0.0 |
Receptor, IGF Type 1/drug effects/*physiology | 2 | 40.0 |
Tyrphostins/pharmacology | 2 | 1.0 |
Neoplasm Transplantation | 3 | 0.0 |
KB Cells | 2 | 2.0 |
Potassium/pharmacology | 2 | 3.0 |
Signal Transduction/*physiology | 2 | 0.0 |
Follicle Stimulating Hormone/blood | 2 | 0.0 |
*Chromosome Mapping | 3 | 0.0 |
DNA Primers/genetics | 2 | 0.0 |
DNA, Satellite/*genetics | 2 | 3.0 |
Hybrid Cells | 3 | 0.0 |
Chromatography, High Pressure Liquid | 5 | 0.0 |
Plasmids | 4 | 0.0 |
Acromegaly/*drug therapy | 2 | 11.0 |
Blood Glucose/analysis | 2 | 0.0 |
*Insulin Resistance | 2 | 1.0 |
Octreotide/*therapeutic use | 3 | 8.0 |
Drug Tolerance | 2 | 1.0 |
Epidermal Growth Factor/metabolism | 3 | 0.0 |
Anthropometry | 3 | 1.0 |
*Chromosomes, Human, Pair 12 | 2 | 0.0 |
Japan | 2 | 0.0 |
*Linkage (Genetics) | 2 | 0.0 |
Age Determination by Skeleton | 2 | 10.0 |
Nitrogen/metabolism | 2 | 8.0 |
Cattle/*genetics | 2 | 1.0 |
Blood Glucose/metabolism | 4 | 0.0 |
Autoradiography | 3 | 0.0 |
Dexamethasone/pharmacology | 2 | 0.0 |
Gene Expression Regulation/drug effects | 2 | 0.0 |
Receptor, Insulin/*genetics | 2 | 5.0 |
Binding, Competitive | 3 | 0.0 |
Genes, Immunoglobulin | 2 | 1.0 |
Growth Hormone/*blood | 3 | 1.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 7 | 0.0 |
*Polymorphism, Genetic | 2 | 0.0 |
Pituitary Neoplasms/*drug therapy | 2 | 10.0 |
Iodine Radioisotopes | 2 | 0.0 |
Hemoglobin A, Glycosylated/analysis | 2 | 0.0 |
Lipoproteins, HDL Cholesterol/blood | 2 | 0.0 |
Octreotide/therapeutic use | 2 | 15.0 |
Prospective Studies | 2 | 0.0 |
Tomography, X-Ray Computed | 2 | 0.0 |
Structure-Activity Relationship | 4 | 0.0 |
Protein-Tyrosine Kinase/*metabolism | 2 | 0.0 |
Proto-Oncogene Proteins/metabolism | 3 | 0.0 |
Receptors, Cell Surface/*metabolism | 2 | 0.0 |
Mice, Nude | 2 | 0.0 |
Cell Transformation, Neoplastic/*genetics | 2 | 1.0 |
DNA/biosynthesis | 2 | 0.0 |
Lipids/*metabolism | 2 | 0.0 |
Hydrogen-Ion Concentration | 2 | 0.0 |
Microscopy, Electron | 2 | 0.0 |
Receptors, Somatomedin | 6 | 13.0 |
Blotting, Western | 3 | 0.0 |
*Saccharomyces cerevisiae Proteins | 2 | 0.0 |
Saccharomyces cerevisiae/genetics | 2 | 0.0 |
Blotting, Southern | 2 | 0.0 |
Crosses, Genetic | 2 | 0.0 |
*Nutritional Status | 2 | 2.0 |
Breast Neoplasms/*metabolism | 2 | 0.0 |
Culture Techniques | 2 | 0.0 |
Insulin-Like Growth Factor I/genetics/metabolism | 2 | 25.0 |
Antibody Specificity | 2 | 0.0 |
Estradiol/metabolism | 2 | 2.0 |
Somatomedins/*pharmacology | 2 | 7.0 |
Breast Neoplasms/*analysis | 2 | 5.0 |
Protein Kinases/*metabolism | 2 | 0.0 |
Immunoblotting | 2 | 0.0 |
Mice, Inbred C57BL | 2 | 0.0 |
Protein Binding | 2 | 0.0 |
